Skip to main content

Nixon Peabody LLP

  • People
  • Capabilities
  • Insights
  • About
Trending Topics
    • People
    • Capabilities
    • Insights
    • About
    • Locations
    • Events
    • Careers
    • Alumni
    Practices

    View All

    • Affordable Housing
    • Community Development Finance
    • Corporate & Finance
    • Cybersecurity & Privacy
    • Entertainment & Media
    • Environmental
    • Franchising & Distribution
    • Government Investigations & White Collar Defense
    • Healthcare
    • Intellectual Property
    • International Services
    • Labor, Employment, and Benefits
    • Litigation
    • Private Wealth & Advisory
    • Project Finance
    • Public Finance
    • Real Estate
    • Regulatory & Government Relations
    Industries

    View All

    • Aviation
    • Cannabis
    • Consumer
    • Energy
    • Financial Services
    • Healthcare
    • Higher Education
    • Infrastructure
    • Manufacturing
    • Nonprofit Organizations
    • Real Estate
    • Sports & Stadiums
    • Technology
    Value-Added Services

    View All

    • Alternative Fee Arrangements

      Developing innovative pricing structures and alternative fee agreement models that deliver additional value for our clients.

    • Continuing Education

      Advancing professional knowledge and offering credits for attorneys, staff and other professionals.

    • Crisis Advisory

      Helping clients respond correctly when a crisis occurs.

    • DEI Strategic Services

      Providing our clients with legal, strategic, and practical advice to make transformational changes in their organizations.

    • eDiscovery

      Leveraging law and technology to deliver sound solutions.

    • Environmental, Social, and Governance (ESG)

      We help clients create positive return on investments in people, products, and the planet.

    • Global Services

      Delivering seamless service through partnerships across the globe.

    • Innovation

      Leveraging leading-edge technology to guide change and create seamless, collaborative experiences for clients and attorneys.

    • IPED

      Industry-leading conferences focused on affordable housing, tax credits, and more.

    • Legal Project Management

      Providing actionable information to support strategic decision-making.

    • Legally Green

      Teaming with clients to advance sustainable projects, mitigate the effects of climate change, and protect our planet.

    • Nixon Peabody Trust Company

      Offering a range of investment management and fiduciary services.

    • NP Capital Connector

      Bringing together companies and investors for tomorrow’s new deals.

    • NP Second Opinion

      Offering fresh insights on cases that are delayed, over budget, or off-target from the desired resolution.

    • NP Trial

      Courtroom-ready lawyers who can resolve disputes early on clients’ terms or prevail at trial before a judge or jury.

    • Social Impact

      Creating positive impact in our communities through increasing equity, access, and opportunity.

    • Women in Dealmaking

      We provide strategic counsel on complex corporate transactions and unite dynamic women in the dealmaking arena.

    1. Home
    2. Insights
    3. Alerts
    4. Gut check: The FDA approves microbiome-based therapies, with future approvals expected

      Alerts

    Alert / Intellectual Property

    Gut check: The FDA approves microbiome-based therapies, with future approvals expected

    May 15, 2023

    LinkedInX (Twitter)EmailCopy URL

    By Mark J. FitzGerald, Ph.D. and Alissa Young, J.D., Ph.D.

    Recent regulatory approvals create a path for a host of microbiome-related products to be developed, patented, and sold.

    What’s the impact?

    • The regulatory approvals of rCDI treatments Biomictra™, Rebyota™, and VOWST™ pave the way for companies to obtain FDA approval for other microbiome-related treatments.
    • We anticipate that patent enforcement and challenges to those patents relating to approved products will lend certainty to the strengths of granted microbiome patent claims, spurring greater investment in microbiome-related products.

    DOWNLOAD

    Learn more about recent regulatory approvals

    The commercial development of new drug therapies relies heavily on patent protection, and while Gut Check generally focuses on patent issues as they affect microbiome-related products, regulatory approval to actually sell the product is the linchpin for commercial viability for any drug. Much of the microbiome space is minimally regulated; in the US, the Food and Drug Administration (FDA) does not currently regulate foods and dietary supplements containing probiotics. However, if a company wants their microbiota therapy designated as a prescribable pharmaceutical and thus potentially covered by health insurance, they must conduct clinical trials and apply for approval by the FDA. In the maturing microbiome therapeutics arena, despite a significant number of ongoing clinical trials, the entire field has been anxiously awaiting the first regulatory approvals.

    That time has finally arrived. Australian regulators approved BiomeBank’s Biomictra™ donor-derived fecal microbiota transplant (FMT) product for the treatment of recurrent Clostridium difficile infection (rCDI) in November of last year, marking the first approved human microbiome therapeutic in the world. In the US, shortly thereafter, on November 22, 2022, the FDA issued its first approval for a microbiome-based human therapy, for Rebyota™ from Ferring Pharmaceuticals Inc. Rebyota™ is a donor-derived, rectally-administered FMT product also approved for use in the treatment of rCDI, which affects 500,000 patients, leads to 30,000 deaths, and costs an estimated $1 billion to $6 billion annually in the US. Treatment with Rebyota™ is estimated to cost $9,000 per dose, which could be reduced to as low as $100 by insurance.

    More recently, on April 26, 2023, the FDA announced the approval of Seres and Nestle’s VOWST™ (also called SER-109) to treat rCDI after the conclusion of the ECOSPOR clinical trials. The VOWST™ capsules contain bacterial spores purified from healthy human donor feces, which have been pre-tested for pathogens. VOWST™ is the first fecal microbiota product approved by the FDA for oral administration. Seres announced that they plan to sell VOWST™ in June 2023 at $17,500 per course of treatment (4 capsules taken orally once daily for 3 consecutive days).

    The regulatory approvals of Biomictra™, Rebyota™, and VOWST™ represent a watershed moment. While they are each directed to the treatment of rCDI, a varied pipeline of different microbiome-related drugs is in clinical trials for a variety of different indications. In the US, the FDA website lists at least 100 active or completed clinical trials that mention “microbiota.” Maat Pharma recently started a Phase 3 trial of MaaT013, an enema-administered FMT therapy, for patients with acute Graft-vs-Host-Disease (GvHD). Therapies in the pipeline also include pharmaceuticals that comprise single species and defined consortia of microorganisms. Such products contrast with the currently approved FMT therapies, which comprise an undefined number of unspecified bacterial species manufactured from donor fecal samples. Although such fecal samples are screened for known pathogens before FMT manufacture, they present more health concerns than single species or consortia-based therapies, which are not isolated from feces and are manufactured using known lab-grown bacteria. FMTs also present issues regarding donor supply and microbiota uniformity and consistency compared to single species or defined consortia therapeutics. As but one example of a consortium therapeutic, Vedanta’s VE202 is in a Phase 2 clinical trial for Ulcerative Colitis.

    Where products are approved and beginning to be sold, we anticipate litigation enforcing microbiome patents to take off. Patent enforcement and challenges to those patents will lend certainty to the strengths (and potential weaknesses) of granted microbiome patent claims. Expect such certainty, combined with the recent and likely ongoing regulatory approvals, to spur greater investment in this space.

    Practices

    Intellectual PropertyLife SciencesPharmaceutical & Medical Device LitigationMicrobiome

    Insights And Happenings

    • Alert

      SCOTUS clarifies use of the First Amendment defense in Jack Daniels Properties v. VIP Products LLC

      June 13, 2023
    • Alert

      SCOTUS reiterates disclosures needed to meet enablement requirement

      May 23, 2023
    • Alert

      DEA proposes regulations for prescribing controlled substances via telemedicine

      March 2, 2023
    The foregoing has been prepared for the general information of clients and friends of the firm. It is not meant to provide legal advice with respect to any specific matter and should not be acted upon without professional counsel. If you have any questions or require any further information regarding these or other related matters, please contact your regular Nixon Peabody LLP representative. This material may be considered advertising under certain rules of professional conduct.

    Subscribe to stay informed of the latest legal news, alerts, and business trends.Subscribe

    • People
    • Capabilities
    • Insights
    • About
    • Locations
    • Events
    • Careers
    • Alumni
    • Cookie Preferences
    • Privacy Policy
    • Terms of Use
    • Accessibility Statement
    • Statement of Client Rights
    • Purchase Order Terms & Conditions
    • Nixon Peabody International LLC
    • PAL
    © 2025 Nixon Peabody. All rights reserved